- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05701709
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
May 28, 2023 updated by: Shanghai Hengrui Pharmaceutical Co., Ltd.
An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of SHR-A2102 in Patients With Advanced Solid Tumors
The study was designed to evaluate the efficacy, safety, and pharmacokinetics of SHR2102 in patients with advanced solid tumors.
The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of SHR-A2102 in phase II study.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fei Luo
- Phone Number: +0518-81220121
- Email: fei.luo@hengrui.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- Shanghai Chest Hospital
-
Principal Investigator:
- Hua Zhong
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Able and willing to provide a written informed consent;
- Age ≥18 years old, gender unlimited;
- The physical status score of the Eastern Tumor Cooperative Group (ECOG) was 0 ~ 1;
- Life expectancy Predicted survival ≥3 months;
- Histologically or cytologically confirmed advanced or metastatic malignant tumor; Patients with advanced solid tumors confirmed by pathology who have failed or been intolerant to standard treatment, have no standard treatment or refuse standard treatment;
- There is at least one measurable lesion that meets the RECIST 1.1 criteria.
Exclusion Criteria:
- Plan to receive any other antitumor therapy during this trial;
- Receiving other investigational drugs or treatments that are not on the market within 4 weeks prior to the initial administration of the study drug;
- Received antitumor therapy such as chemotherapy, radiotherapy, biotherapy, targeted therapy, or immunotherapy within 4 weeks prior to first administration of the study drug (nitrosourea or mitomycin C within 6 weeks prior to first administration; Oral fluorouracil within 2 weeks prior to initial first administration); Palliative radiotherapy or local therapy within 2 weeks before first administration use of the study drug;
- Had major surgery other than diagnosis or biopsy within 4 weeks prior to the study's initial dosing;
- Treatment with CYP3A4, CYP2D6, P-gp or BCRP booster or inducer is less than 5 drug half-life from the date of first administration;
- According to NCI-CTCAE v5.0, adverse events caused by previous antitumor therapy did not recover to ≤ grade 1 (except hair loss; In the judgment of the investigator, after consultation with the sponsor, some tolerable chronic grade 2 toxicity may be excluded);
- Inadequately treated central nervous system (CNS) metastases, or the presence of uncontrolled or symptomatic active CNS metastases, may be characterized by the presence of clinical symptoms, cerebral edema, spinal cord compression, cancerous meningitis, pia meningeal disease, and/or rapid progression. Patients with CNS metastases that have been adequately treated and whose neurological symptoms return to baseline at least 4 weeks prior to randomization (except for residual signs or symptoms associated with CNS treatment) may be enrolled. In addition, subjects must either stop corticosteroids or receive prednisone (or an equivalent dose of another corticosteroid) at least 4 weeks prior to randomization;
- Any other malignancies, excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix, etc. within 5 years prior to initial administration;
- A history of clinically significant lung disease (such as interstitial pneumonia, radiation pneumonia, pulmonary fibrosis) or chest imaging during screening suggests any such disease;
- Severe infections that require intravenous antibiotic, antiviral or antifungal control;
- Active HBV or HCV infection (HBsAg positive and viral copy number ≥2000 IU/mL, HCV antibody positive and HCV RNA higher than the lower limit of detection method);
- History of immunodeficiency (including HIV positive, other acquired or congenital immunodeficiency diseases) or organ transplantation;
- Concomitant diseases (such as severe diabetes, thyroid disease, and psychosis) or any other conditions that, in the investigator's judgment, seriously endanger the patient's safety or affect the patient's ability to complete the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR-A2102
|
SHR-A2102 was given intravenously.
Patients may continue to use SHR-A2102 until disease progression or unacceptable toxicity occurs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events
Time Frame: 24 months
|
Adverse events are assessed by CTCAE v5.0
|
24 months
|
Maximum tolerated dose (MTD)
Time Frame: 12 weeks
|
MTD is defined as the maximum dose within the first 3 weeks of multiple dosing that does not exceed the proportion of subjects who develop DLT as specified in the protocol's BOIN design.
|
12 weeks
|
Recommended Phase 2 dose (RP2D)
Time Frame: 24 months
|
RP2D will be determined based on the available data for toxicity and PK.
|
24 months
|
Dose Limiting Toxicity (DLT)
Time Frame: 3 weeks
|
Adverse events that occurred during the DLT observation period (the first period of study administration, a total of 21 days) that were determined to be related to the study drug (see protocol for details).
|
3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: 24 months
|
24 months
|
|
Peak plasma concentration (Cmax)
Time Frame: 12 weeks
|
12 weeks
|
|
Area under the plasma concentration versus time curve (AUC)
Time Frame: 12 weeks
|
12 weeks
|
|
T1/2 (Half-life)
Time Frame: 12 weeks
|
The time required for the plasma concentration of a drug to be reduced by 50%
|
12 weeks
|
Immunogenicity: Number of subjects with anti-SHR-A2102 antibody (ADA), incidence, occurrence time, duration, etc
Time Frame: 12 weeks
|
12 weeks
|
|
duration of response (DoR)
Time Frame: 24 months
|
24 months
|
|
disease control rate (DCR)
Time Frame: 24 months
|
24 months
|
|
progression-free survival (PFS)
Time Frame: 24 months
|
24 months
|
|
overall survival (OS)
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 6, 2023
Primary Completion (Estimated)
August 31, 2025
Study Completion (Estimated)
August 31, 2025
Study Registration Dates
First Submitted
January 18, 2023
First Submitted That Met QC Criteria
January 18, 2023
First Posted (Actual)
January 27, 2023
Study Record Updates
Last Update Posted (Actual)
May 31, 2023
Last Update Submitted That Met QC Criteria
May 28, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR-A2102-I-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
Clinical Trials on SHR-A2102
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingAdvanced Or Metastatic Solid Tumor MalignanciesChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedAdvanced MalignanciesAustralia, China
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Tianjin Medical University Cancer Institute and...Not yet recruitingEsophageal Squamous Cell Carcinoma | Progression to PD-1 AntibodyChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingAlzheimer's DiseaseChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingAsthma With Eosinophilic PhenotypeChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPrimary Hypercholesterolemia | Mixed HyperlipemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPrimary HypercholesterolemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingNasopharyngeal CarcinomaChina